Abstract
ackground: Due to the absence of an etiologic treatment for SARS-CoV-2 and the troubles associated with growing new medications, a few medications previously endorsed for different infections or with adequacy against SARS and MERS, have been utilized in patients with COVID-19. This precise audit intends to sum up proof on the adequacy and wellbeing of five antivirals applied to patients with COVID-19, that have demonstrated to be powerful either in vitro contemplates or in investigations on SARS-CoV and MERS.; Methods: A concentrated hunt of various data sets (Pub Med, WoS, MEDLINE and Cochrane COVID-19 Study Register) has been done until the finish of April 2021. This efficient audit has been led by the PRISMA proclamation. From every one of the included examinations, the qualities of the mediation and correlation gatherings, segment information and results were removed autonomously; Results: Remdesivir is very much endured and assists with speeding up clinical improvement yet is insufficient in diminishing mortality. Favipiravir is protected and shows promising outcomes with respect to indication goal yet doesn’t work on viral leeway. The utilization of lopinavir/ritonavir has been related with an expanded danger of gastrointestinal unfavorable occasions and it has not demonstrated to be powerful. No critical contrasts were seen between patients treated with ribavirin or umifenovir and their individual benchmark groups; Conclusions: Remdesivir and favipiravir are all around endured and successful in speeding up clinical improvement. This deliberate survey doesn’t uphold the utilization of lopinavir/ritonavir, ribavirin and umifenovir in hospitalized patients with COVID-19. View Full-Text
Catchphrases: SARS-CoV-2; COVID-19; treatment; antiviral; remdesivir; lopinavir/ritonavir; favipiravir; ribavirin; umifenovir; arbidol; viability; safet
